Incyte (INCY) ROIC: History & Chart

Name: Incyte Corporation (INCY) Return on Invested Capital (ROIC) — historical time series
Creator: TGMCharts

Compare

Incyte Corporation(INCY)

Biotechnology · Wilmington, DE

$125.31-2.31 (-1.81%)

Delayed quote: Sep 18, 2026, 4:00 PM EDT

Compare

About Incyte Corporation

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Wilmington, DE

2,844 employees

www.incyte.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: William J. Meury

View full financials

INCY Return on Invested Capital (ROIC) Metrics

RETURN ON INVESTED CAPITAL (ROIC)

22.95%

RETURN ON INVESTED CAPITAL (ROIC) AVG TTM

19.12%

RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y

9.76%

RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y

10.80%

RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y

5.97%

RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y

4.29%

RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y

-3.82%

CURRENT VS TTM AVG

+20.07%

CURRENT VS 3Y AVG

+135.08%

CURRENT VS 5Y AVG

+112.54%

CURRENT VS 10Y AVG

+284.47%

CURRENT VS 15Y AVG

+434.84%

CURRENT VS 20Y AVG

+700.23%

SECTOR MEDIAN · HEALTHCARE

8.75%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

+162.46%

vs the sector median at left

NAME	MARKET CAP	RETURN ON INVESTED CAPITAL (ROIC)	TTM	3Y	5Y
Incyte Corporation (INCY)	$25.40B	22.95%	19.12%	9.76%	10.80%
West Pharmaceutical Services, Inc. (WST)vs ›	$25.49B	15.77%	14.65%	16.96%	17.76%
Labcorp Holdings Inc. (LH)vs ›	$26.30B	8.02%	6.33%	5.68%	7.63%
BioNTech SE (BNTX)vs ›	$24.13B	-10.37%	-4.85%	9.52%	19.51%
Medline Inc. (MDLN)vs ›	$26.75B	4.05%	6.03%	5.27%	5.27%
Quest Diagnostics Incorporated (DGX)vs ›	$27.20B	8.25%	7.70%	8.24%	10.04%
Mettler-Toledo International Inc. (MTD)vs ›	$28.14B	38.57%	38.26%	37.51%	36.01%
GE HealthCare Technologies Inc. (GEHC)vs ›	$28.97B	6.94%	7.96%	8.07%	9.18%
United Therapeutics Corporation (UTHR)vs ›	$21.00B	17.69%	15.79%	14.57%	13.09%
Zoetis Inc. (ZTS)vs ›	$29.95B	21.63%	21.87%	20.30%	19.27%

NAME

MARKET CAP

RETURN ON INVESTED CAPITAL (ROIC)

TTM

Incyte Corporation (INCY)

$25.40B

22.95%

19.12%

9.76%

10.80%

West Pharmaceutical Services, Inc. (WST)vs ›

$25.49B

15.77%

14.65%

16.96%

17.76%

Labcorp Holdings Inc. (LH)vs ›

$26.30B

8.02%

6.33%

5.68%

7.63%

BioNTech SE (BNTX)vs ›

$24.13B

-10.37%

-4.85%

9.52%

19.51%

Medline Inc. (MDLN)vs ›

$26.75B

4.05%

6.03%

5.27%

Quest Diagnostics Incorporated (DGX)vs ›

$27.20B

8.25%

7.70%

8.24%

10.04%

Mettler-Toledo International Inc. (MTD)vs ›

$28.14B

38.57%

38.26%

37.51%

36.01%

GE HealthCare Technologies Inc. (GEHC)vs ›

$28.97B

6.94%

7.96%

8.07%

9.18%

United Therapeutics Corporation (UTHR)vs ›

$21.00B

17.69%

15.79%

14.57%

13.09%

Zoetis Inc. (ZTS)vs ›

$29.95B

21.63%

21.87%

20.30%

19.27%

Return on Invested Capital (ROIC) Formula & Definition

ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)

Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.

Return on Invested Capital (ROIC) FAQ

What is the return on invested capital (ROIC) for Incyte Corporation (INCY)?

The return on invested capital (ROIC) for INCY stock is 22.95%.

Is Incyte Corporation's return on invested capital (ROIC) high or low?

The return on invested capital (ROIC) of 22.95% is 113% above its 5-year average of 10.80%, near the high end of its 5-year range (-0.83%–22.95%).

What is the TTM average return on invested capital (ROIC) for Incyte Corporation (INCY)?

The TTM average return on invested capital (ROIC) for INCY stock is 19.12%.

What is the 3Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?

The 3Y average return on invested capital (ROIC) for INCY stock is 9.76%.

What is the 5Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?

The 5Y average return on invested capital (ROIC) for INCY stock is 10.80%.

What is the 10Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?

The 10Y average return on invested capital (ROIC) for INCY stock is 5.97%.

What is the 15Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?

The 15Y average return on invested capital (ROIC) for INCY stock is 4.29%.

What is the 20Y average return on invested capital (ROIC) for Incyte Corporation (INCY)?

The 20Y average return on invested capital (ROIC) for INCY stock is -3.82%.

DATE	RETURN ON INVESTED CAPITAL (ROIC)
2026-06-30	22.95%
2026-03-31	20.01%
2025-12-31	19.04%
2025-09-30	18.83%
2025-06-30	14.74%
2025-03-31	2.48%
2024-12-31	0.83%
2024-09-30	-0.83%
2024-06-30	0.26%
2024-03-31	8.77%
2023-12-31	8.02%
2023-09-30	6.31%
2023-06-30	5.50%
2023-03-31	6.47%
2022-12-31	7.96%
2022-09-30	13.77%
2022-06-30	16.33%
2022-03-31	14.48%
2021-12-31	14.36%
2021-09-30	15.99%
2021-06-30	10.50%
2021-03-31	14.53%
2020-12-31	-9.00%
2020-09-30	-12.27%
2020-06-30	-7.62%
2020-03-31	-14.82%
2019-12-31	12.59%
2019-09-30	13.26%
2019-06-30	10.77%
2019-03-31	11.02%
2018-12-31	5.52%
2018-09-30	-4.05%
2018-06-30	-4.98%
2018-03-31	-9.18%
2017-12-31	-12.59%
2017-09-30	-3.35%
2017-06-30	-4.58%
2017-03-31	-1.86%
2016-12-31	10.31%
2016-09-30	12.62%
2016-06-30	11.68%
2016-03-31	10.14%
2015-12-31	5.22%
2015-09-30	-5.16%
2015-06-30	3.75%
2015-03-31	1.55%
2014-12-31	-0.69%
2014-09-30	0.71%
2014-06-30	-13.85%
2014-03-31	-6.24%
2013-12-31	-3.09%
2013-09-30	12.22%
2013-06-30	14.42%
2013-03-31	14.95%
2012-12-31	0.59%
2012-09-30	-43.42%
2012-06-30	-57.83%
2012-03-31	-100.44%
2011-12-31	-74.05%
2011-09-30	-22.67%
2011-06-30	-11.99%
2011-03-31	5.17%
2010-12-31	3.74%
2010-09-30	-20.02%
2010-06-30	-20.64%
2010-03-31	-32.58%
2009-12-31	-24.12%
2009-09-30	-32.95%
2009-06-30	-131.79%
2009-03-31	-106.69%
2008-12-31	-87.50%
2008-09-30	-64.34%
2008-06-30	-77.04%
2008-03-31	-49.89%
2007-12-31	-35.67%
2007-09-30	-31.03%
2007-06-30	-26.53%
2007-03-31	-26.21%
2006-12-31	-25.26%
2006-09-30	-19.99%
2006-06-30	-29.85%
2006-03-31	-30.03%
2005-12-31	-29.11%
2005-09-30	-29.20%
2005-06-30	-24.22%
2005-03-31	-28.51%
2004-12-31	-30.49%
2004-09-30	-37.09%
2004-06-30	-34.46%
2004-03-31	-23.95%
2003-12-31	-44.23%
2003-09-30	-35.92%
2003-06-30	-33.56%

DATE

RETURN ON INVESTED CAPITAL (ROIC)

2026-06-30

22.95%

2026-03-31

20.01%

2025-12-31

19.04%

2025-09-30

18.83%

2025-06-30

14.74%

2025-03-31

2.48%

2024-12-31

0.83%

2024-09-30

-0.83%

2024-06-30

0.26%

2024-03-31

8.77%

2023-12-31

8.02%

2023-09-30

6.31%

2023-06-30

5.50%

2023-03-31

6.47%

2022-12-31

7.96%

2022-09-30

13.77%

2022-06-30

16.33%

2022-03-31

14.48%

2021-12-31

14.36%

2021-09-30

15.99%

2021-06-30

10.50%

2021-03-31

14.53%

2020-12-31

-9.00%

2020-09-30

-12.27%

2020-06-30

-7.62%

2020-03-31

-14.82%

2019-12-31

12.59%

2019-09-30

13.26%

2019-06-30

10.77%

2019-03-31

11.02%

2018-12-31

5.52%

2018-09-30

-4.05%

2018-06-30

-4.98%

2018-03-31

-9.18%

2017-12-31

-12.59%

2017-09-30

-3.35%

2017-06-30

-4.58%

2017-03-31

-1.86%

2016-12-31

10.31%

2016-09-30

12.62%

2016-06-30

11.68%

2016-03-31

10.14%

2015-12-31

5.22%

2015-09-30

-5.16%

2015-06-30

3.75%

2015-03-31

1.55%

2014-12-31

-0.69%

2014-09-30

0.71%

2014-06-30

-13.85%

2014-03-31

-6.24%

2013-12-31

-3.09%

2013-09-30

12.22%

2013-06-30

14.42%

2013-03-31

14.95%

2012-12-31

0.59%

2012-09-30

-43.42%

2012-06-30

-57.83%

2012-03-31

-100.44%

2011-12-31

-74.05%

2011-09-30

-22.67%

2011-06-30

-11.99%

2011-03-31

5.17%

2010-12-31

3.74%

2010-09-30

-20.02%

2010-06-30

-20.64%

2010-03-31

-32.58%

2009-12-31

-24.12%

2009-09-30

-32.95%

2009-06-30

-131.79%

2009-03-31

-106.69%

2008-12-31

-87.50%

2008-09-30

-64.34%

2008-06-30

-77.04%

2008-03-31

-49.89%

2007-12-31

-35.67%

2007-09-30

-31.03%

2007-06-30

-26.53%

2007-03-31

-26.21%

2006-12-31

-25.26%

2006-09-30

-19.99%

2006-06-30

-29.85%

2006-03-31

-30.03%

2005-12-31

-29.11%

2005-09-30

-29.20%

2005-06-30

-24.22%

2005-03-31

-28.51%

2004-12-31

-30.49%

2004-09-30

-37.09%

2004-06-30

-34.46%

2004-03-31

-23.95%

2003-12-31

-44.23%

2003-09-30

-35.92%

2003-06-30

-33.56%

Return on Invested Capital (ROIC): 22.95%

INCY Return on Invested Capital (ROIC)

INCY Average Return on Invested Capital (ROIC) Chart

INCY Current vs Average Return on Invested Capital (ROIC) Chart

INCY Return on Invested Capital (ROIC) Metrics

INCY Competitors' Return on Invested Capital (ROIC)

Capital Efficiency

Return on Invested Capital (ROIC) Formula & Definition

Return on Invested Capital (ROIC) FAQ

INCY Return on Invested Capital (ROIC) History

Related Metrics